Novel multi‑cancer early detection test with $3,000 price point, no established reimbursement pathway, limited clinical evidence, payer skepticism, and competitive landscape.
Comprehensive market access strategy with health economics research, clinical utility studies, payer engagement, coverage policy development, provider education, and launch execution.
- Coverage obtained from payers representing 85% of target population
- Average time‑to‑coverage decision: 6 months (vs 12‑18 month industry average)
- $25M first‑year revenue with 60% positive coverage rate
Proves that systematic market access strategy can overcome reimbursement barriers for novel high‑cost diagnostics.
- Health economics study demonstrating $50,000 cost per QALY
- Clinical utility evidence from 10,000‑patient registry
- Value‑based contracting with 3 major national payers
